首页> 外文期刊>Microbial Cell Factories >A strategy to identify a ketoreductase that preferentially synthesizes pharmaceutically relevant ( S )-alcohols using whole-cell biotransformation
【24h】

A strategy to identify a ketoreductase that preferentially synthesizes pharmaceutically relevant ( S )-alcohols using whole-cell biotransformation

机译:一种识别可通过全细胞生物转化优先合成药学相关(S)醇的酮还原酶的策略

获取原文
       

摘要

Chemical industries are constantly in search of an expeditious and environmentally benign method for producing chiral synthons. Ketoreductases have been used as catalysts for enantioselective conversion of desired prochiral ketones to their corresponding alcohol. We chose reported promiscuous ketoreductases belonging to different protein families and expressed them in E.?coli to evaluate their ability as whole-cell catalysts for obtaining chiral alcohol intermediates of pharmaceutical importance. Apart from establishing a method to produce high value (S)-specific alcohols that have not been evaluated before, we propose an in silico analysis procedure?to predict product chirality. Six enzymes originating from Sulfolobus?sulfotaricus, Zygosaccharomyces?rouxii, Hansenula?polymorpha, Corynebacterium sp. ST-10, Synechococcus sp. PCC?7942 and Bacillus sp. ECU0013 with reported efficient activity for dissimilar substrates are compared here to arrive at an optimal enzyme for the method. Whole–cell catalysis of ketone intermediates for drugs like Aprepitant, Sitagliptin and Dolastatin using E.?coli over-expressing these enzymes yielded (S)-specific chiral alcohols. We explain this chiral specificity for the best-performing enzyme, i.e., Z.?rouxii ketoreductase using in silico modelling and MD simulations. This rationale was applied to five additional ketones that are used in the synthesis of Crizotinib, MA-20565?(an antifungal agent), Sulopenem, Rivastigmine, Talampanel and Barnidipine and predicted the yield of (S) enantiomers. Experimental evaluation matched the in silico analysis wherein?~?95% (S)-specific alcohol with a chemical yield of 23–79% was obtained through biotransformation. Further, the cofactor re-cycling was optimized by switching the carbon source from glucose to sorbitol that improved the chemical yield to 85–99%. Here, we present a strategy to synthesize pharmaceutically relevant chiral alcohols by ketoreductases using a cofactor balanced whole-cell catalysis scheme that is useful for the industry. Based on the results obtained in these trials, Zygosaccharomyces?rouxii ketoreductase was identified as a proficient enzyme to obtain (S)-specific alcohols from their respective ketones. The whole–cell catalyst when combined with nutrient modulation of using sorbitol as a carbon source helped obtain high enantiomeric and chemical yield.
机译:化学工业一直在寻找一种快速且对环境无害的生产手性合成子的方法。酮还原酶已经用作催化剂,用于将所需的前手性酮对映体转化为它们相应的醇。我们选择了属于不同蛋白质家族的报道的混杂酮还原酶,并在大肠杆菌中表达它们,以评估其作为全细胞催化剂获得具有重要药学意义的手性醇中间体的能力。除了建立生产以前未评估过的高价值(S)特定醇的方法外,我们还提出了计算机分析程序以预测产品的手性。六种酶分别来自Sulfolobus?sulfotaricus,Zygosaccharomyces?rouxii,Hansenula?polymorpha,Corynebacterium sp.。 ST-10,Synocococcus sp.。 PCC?7942和芽孢杆菌在此对具有报道的对不同底物的有效活性的ECU0013进行比较,以得出该方法的最佳酶。使用过量表达这些酶的大肠杆菌对诸如阿瑞匹坦,西他列汀和杜拉汀等药物的酮中间体进行全细胞催化,产生了(S)特异性手性醇。我们使用计算机模拟和MD模拟解释了对表现最佳的酶,即鲁西耶氏酵母酮还原酶的手性特异性。该原理适用于另外五种酮,这些酮用于合成克唑替尼,MA-20565?(抗真菌剂),舒洛培南,利伐斯明,塔拉潘奈尔和巴尼地平,并预测(S)对映异构体的产率。实验评估与计算机分析相吻合,其中通过生物转化获得了?〜?95%(S)特异性醇,化学收率为23–79%。此外,通过将碳源从葡萄糖转换为山梨糖醇,可以优化辅因子的再循环,从而将化学收率提高到85-99%。在这里,我们提出了一种策略,该方法使用辅助因子平衡的全细胞催化方案,通过酮还原酶合成可药用的手性醇,该方法对工业有用。根据在这些试验中获得的结果,酵母属鲁西酮还原酶被鉴定为从各自的酮中获得(S)特异性醇的有效酶。全细胞催化剂与使用山梨醇作为碳源的营养调节相结合,有助于获得高对映体和化学收率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号